Back to top
more

Cartesian Therapeutics, Inc. (RNAC)

(Real Time Quote from BATS)

$26.19 USD

26.19
25,938

+1.59 (6.46%)

Updated May 22, 2024 01:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for RNAC

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Cartesian Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 77 135 128 139 90
Receivables 9 10 10 7 5
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 5 4 6 5 2
Total Current Assets 91 148 144 151 97
Net Property & Equipment 2 3 2 1 1
Investments & Advances 2 2 2 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 48 0 0 0 0
Deposits & Other Assets 152 1 1 2 1
Total Assets 305 166 160 165 100
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 3 0 0 0 1
Current Portion Long-Term Debt 0 8 6 0 19
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 16 14 11 8 13
Income Taxes Payable 0 0 1 0 0
Other Current Liabilities 47 1 54 72 2
Total Current Liabilities 68 25 72 82 35
Mortgages 0 0 0 0 0
Deferred Taxes/Income 19 0 11 39 15
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 18 20 25 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 348 19 25 29 42
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 445 72 137 183 91
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 301 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 179 493 457 391 349
Retained Earnings -615 -395 -430 -405 -336
Other Equity -5 -5 -5 -5 -5
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -140 94 23 -18 8
Total Liabilities & Shareholder's Equity 305 166 160 165 100
Total Common Equity -440 94 23 -18 8
Shares Outstanding 5.30 5.10 3.80 3.60 2.80
Book Value Per Share -83.05 18.40 5.93 -5.00 3.00

Fiscal Year End for Cartesian Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents 103 77 80 112 126
Receivables 4 9 7 6 9
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 3 5 3 4 4
Total Current Assets 111 91 90 123 138
Net Property & Equipment 2 2 2 3 3
Investments & Advances 2 2 2 2 2
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 48 48 0 0 0
Deposits & Other Assets 152 152 1 1 1
Total Assets 325 305 106 140 156
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable 0 0 0 0 0
Accounts Payable 3 3 0 0 1
Current Portion Long-Term Debt 0 0 0 10 10
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 10 16 14 13 9
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 22 47 4 4 4
Total Current Liabilities 37 68 20 29 27
Mortgages 0 0 0 0 0
Deferred Taxes/Income 16 19 4 5 6
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 14 16
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 381 13 17 23
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 442 445 46 74 81
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock 0 301 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 559 179 502 498 496
Retained Earnings -671 -615 -437 -428 -417
Other Equity -5 -5 -5 -5 -5
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -117 -140 60 65 75
Total Liabilities & Shareholder's Equity 325 305 106 140 156
Total Common Equity -117 -440 60 65 75
Shares Outstanding 5.30 5.30 5.10 5.10 5.10
Book Value Per Share -22.04 -83.05 11.83 12.83 14.62